Fig 1: Effect of PLK4-siRNA on 5-FU sensitivity in CRC cell lines. (A) Comparison of the mRNA expression of PLK4 among blank control, NC-siRNA and PLK4-siRNA-treated HCT-116 cells. One-way ANOVA followed by Tukey's multiple comparisons test was applied. (B) Comparison of cell viability among blank control, NC-siRNA and PLK4-siRNA-treated HCT-116 cells groups. One-way ANOVA followed by Dunnett's multiple comparisons test was applied. (C) Changes in the IC50 value of 5-FU between NC-siRNA and PLK4-siRNA-treated HCT-116 cells. Student's t-test was applied. (D) Comparison of the mRNA expression of PLK4 among blank control, NC-siRNA and PLK4-siRNA-treated LoVo cells. One-way ANOVA followed by Tukey's multiple comparisons test was applied. (E) Comparison of cell viability among blank control, NC-siRNA and PLK4-siRNA-treated LoVo cell groups. One-way ANOVA followed by Dunnett's multiple comparisons test was applied. (F) Changes in the IC50 value of 5-FU between NC-siRNA and PLK4-siRNA-treated LoVo cells. Student's t-test was applied. PLK4, polo-like kinase 4; 5-FU, 5-fluorouracil; CRC, colorectal cancer; IC50, 50% inhibitory concentration; siRNA, short interfering RNA; NC, negative control.